S&P 500   4,081.77 (+0.04%)
DOW   34,418.64 (-0.49%)
QQQ   293.95 (+0.20%)
AAPL   148.79 (+0.51%)
MSFT   255.84 (+0.27%)
META   120.82 (+2.30%)
GOOGL   101.33 (+0.34%)
AMZN   95.57 (-1.00%)
TSLA   194.39 (-0.16%)
NVDA   172.18 (+1.74%)
NIO   12.12 (-5.16%)
BABA   86.37 (-1.36%)
AMD   77.43 (-0.26%)
T   19.17 (-0.57%)
MU   55.61 (-3.54%)
CGC   3.90 (+7.73%)
F   14.07 (+1.22%)
GE   85.41 (-0.65%)
DIS   98.60 (+0.75%)
AMC   8.46 (+17.01%)
PYPL   78.38 (-0.04%)
PFE   51.06 (+1.86%)
NFLX   318.40 (+4.21%)
S&P 500   4,081.77 (+0.04%)
DOW   34,418.64 (-0.49%)
QQQ   293.95 (+0.20%)
AAPL   148.79 (+0.51%)
MSFT   255.84 (+0.27%)
META   120.82 (+2.30%)
GOOGL   101.33 (+0.34%)
AMZN   95.57 (-1.00%)
TSLA   194.39 (-0.16%)
NVDA   172.18 (+1.74%)
NIO   12.12 (-5.16%)
BABA   86.37 (-1.36%)
AMD   77.43 (-0.26%)
T   19.17 (-0.57%)
MU   55.61 (-3.54%)
CGC   3.90 (+7.73%)
F   14.07 (+1.22%)
GE   85.41 (-0.65%)
DIS   98.60 (+0.75%)
AMC   8.46 (+17.01%)
PYPL   78.38 (-0.04%)
PFE   51.06 (+1.86%)
NFLX   318.40 (+4.21%)
S&P 500   4,081.77 (+0.04%)
DOW   34,418.64 (-0.49%)
QQQ   293.95 (+0.20%)
AAPL   148.79 (+0.51%)
MSFT   255.84 (+0.27%)
META   120.82 (+2.30%)
GOOGL   101.33 (+0.34%)
AMZN   95.57 (-1.00%)
TSLA   194.39 (-0.16%)
NVDA   172.18 (+1.74%)
NIO   12.12 (-5.16%)
BABA   86.37 (-1.36%)
AMD   77.43 (-0.26%)
T   19.17 (-0.57%)
MU   55.61 (-3.54%)
CGC   3.90 (+7.73%)
F   14.07 (+1.22%)
GE   85.41 (-0.65%)
DIS   98.60 (+0.75%)
AMC   8.46 (+17.01%)
PYPL   78.38 (-0.04%)
PFE   51.06 (+1.86%)
NFLX   318.40 (+4.21%)
S&P 500   4,081.77 (+0.04%)
DOW   34,418.64 (-0.49%)
QQQ   293.95 (+0.20%)
AAPL   148.79 (+0.51%)
MSFT   255.84 (+0.27%)
META   120.82 (+2.30%)
GOOGL   101.33 (+0.34%)
AMZN   95.57 (-1.00%)
TSLA   194.39 (-0.16%)
NVDA   172.18 (+1.74%)
NIO   12.12 (-5.16%)
BABA   86.37 (-1.36%)
AMD   77.43 (-0.26%)
T   19.17 (-0.57%)
MU   55.61 (-3.54%)
CGC   3.90 (+7.73%)
F   14.07 (+1.22%)
GE   85.41 (-0.65%)
DIS   98.60 (+0.75%)
AMC   8.46 (+17.01%)
PYPL   78.38 (-0.04%)
PFE   51.06 (+1.86%)
NFLX   318.40 (+4.21%)

Edwards Lifesciences - EW Stock Forecast, Price & News

$77.52
+0.27 (+0.35%)
(As of 12/1/2022 03:04 PM ET)
Add
Compare
Today's Range
$77.06
$78.52
50-Day Range
$68.54
$87.44
52-Week Range
$67.13
$131.73
Volume
118,692 shs
Average Volume
5.93 million shs
Market Capitalization
$47.93 billion
P/E Ratio
33.41
Dividend Yield
N/A
Price Target
$106.75

Edwards Lifesciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.79 Rating Score
Upside/​Downside
37.2% Upside
$106.75 Price Target
Short Interest
Healthy
1.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.05mentions of Edwards Lifesciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$7.64 M Sold Last Quarter
Proj. Earnings Growth
2.45%
From $2.45 to $2.51 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.87 out of 5 stars

Medical Sector

39th out of 1,047 stocks

Surgical Appliances & Supplies Industry

3rd out of 23 stocks

EW stock logo

About Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Stock News Headlines

S&P 500 Component DexCom Set For Further Price, Earnings Growth (EW)
Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023.
Edwards Life Sciences Stock Disaster Could Be Your Bounty
Heart disease equipment maker Edwards Life Sciences (NYSE: EW) stock has fallen (-46%) on the year after a disastrous reaction to its Q3 2022 earnings report.
A $226B Copper Spending Jackpot
On November 15, 2021, President Biden signed the biggest infrastructure spending bill of all time. A staggering $226 BILLION is earmarked for projects requiring huge amounts of copper. Turns out, copper is a desperately needed mineral to power the green revolution of clean, renewable energy.
15 Analysts Have This to Say About Edwards Lifesciences
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
2 Medical Device Stocks That Are Steals Right Now
Edwards Lifesciences: Opening My Heart
Edwards Lifesciences (EW) Q3 Earnings Miss, Margins Rise
Edwards Lifesciences Is Seeing Downside Price Targets
Edwards Lifesciences Corp. Q3 Profit Increases, but misses estimates
Edwards Lifesciences Cuts FY22 Outlook; Shares Tank 10%
See More Headlines
Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Company Calendar

Last Earnings
10/27/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
1/25/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
28176E10
Employees
15,700
Year Founded
1958

Price Target and Rating

Average Stock Price Forecast
$106.75
High Stock Price Forecast
$144.00
Low Stock Price Forecast
$73.00
Forecasted Upside/Downside
+37.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
24 Analysts

Profitability

Net Income
$1.50 billion
Pretax Margin
31.40%

Debt

Sales & Book Value

Annual Sales
$5.23 billion
Cash Flow
$2.55 per share
Book Value
$10.06 per share

Miscellaneous

Free Float
610,284,000
Market Cap
$47.93 billion
Optionable
Optionable
Beta
1.05

Social Links


Key Executives

  • Mr. Michael A. MussallemMr. Michael A. Mussallem (Age 69)
    Chairman & CEO
    Comp: $2.88M
  • Mr. Scott B. UllemMr. Scott B. Ullem (Age 55)
    Corp. VP & CFO
    Comp: $1.32M
  • Mr. Donald E. Bobo Jr.Mr. Donald E. Bobo Jr. (Age 60)
    Corp. VP of Strategy & Corp. Devel.
    Comp: $1.26M
  • Mr. Larry L. WoodMr. Larry L. Wood (Age 56)
    Corp. VP of Transcatheter Aortic Valve Replacement
    Comp: $1.31M
  • Mr. Jean-Luc LemercierMr. Jean-Luc Lemercier (Age 65)
    Corp. VP of Europe, Middle East, Africa, Canada & Latin America
    Comp: $1.43M
  • Dr. Todd J. Brinton
    Corp. VP of Advanced Technology & Chief Scientific Officer
  • Mark Wilterding
    VP of Investor Relations
  • Mr. Arnold A. Pinkston (Age 63)
    Corp. VP & Gen. Counsel
  • Mr. Dirksen J. Lehman
    Corp. VP of Public Affairs
  • Ms. Christine Z. McCauley (Age 57)
    Corp. VP of HR













EW Stock - Frequently Asked Questions

Should I buy or sell Edwards Lifesciences stock right now?

24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 5 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EW shares.
View EW analyst ratings
or view top-rated stocks.

What is Edwards Lifesciences' stock price forecast for 2023?

24 brokers have issued 12-month price targets for Edwards Lifesciences' stock. Their EW share price forecasts range from $73.00 to $144.00. On average, they expect the company's share price to reach $106.75 in the next year. This suggests a possible upside of 37.6% from the stock's current price.
View analysts price targets for EW
or view top-rated stocks among Wall Street analysts.

How have EW shares performed in 2022?

Edwards Lifesciences' stock was trading at $129.55 at the beginning of 2022. Since then, EW stock has decreased by 40.1% and is now trading at $77.60.
View the best growth stocks for 2022 here
.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a increase in short interest in October. As of October 31st, there was short interest totaling 8,110,000 shares, an increase of 8.9% from the October 15th total of 7,450,000 shares. Based on an average daily volume of 3,730,000 shares, the days-to-cover ratio is currently 2.2 days. Approximately 1.3% of the company's stock are short sold.
View Edwards Lifesciences' Short Interest
.

When is Edwards Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 25th 2023.
View our EW earnings forecast
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) released its quarterly earnings results on Wednesday, October, 27th. The medical research company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.53 by $0.01. The medical research company earned $1.31 billion during the quarter, compared to analysts' expectations of $1.32 billion. Edwards Lifesciences had a net margin of 27.20% and a trailing twelve-month return on equity of 24.75%. The business's revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.51 earnings per share.
Read the conference call transcript
.

When did Edwards Lifesciences' stock split?

Shares of Edwards Lifesciences split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were distributed to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share (EPS) guidance of $2.40-$2.50 for the period, compared to the consensus EPS estimate of $2.51. The company issued revenue guidance of $5.35 billion-$5.35 billion, compared to the consensus revenue estimate of $5.47 billion.

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.48%), Vanguard Group Inc. (8.23%), State Street Corp (4.34%), Bank of New York Mellon Corp (3.28%), Alliancebernstein L.P. (2.78%) and Brown Advisory Inc. (2.30%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends
.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $77.60.

How much money does Edwards Lifesciences make?

Edwards Lifesciences (NYSE:EW) has a market capitalization of $47.98 billion and generates $5.23 billion in revenue each year. The medical research company earns $1.50 billion in net income (profit) each year or $2.32 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

The company employs 15,700 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?
The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.
Read More
How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525.

This page (NYSE:EW) was last updated on 12/1/2022 by MarketBeat.com Staff